FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer
The Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and…
Browsing: trastuzumab
ASCO 2020: Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol…
ASCO 2020: Trastuzumab combined with trimodality treatment does not improve outcomes for patient
Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the…
Statins may protect against the heart harms of breast cancer therapies
Statins are widely used to lower cholesterol and prevent heart disease and related deaths, but…
Obesity is a risk factor for cardiotoxicity in chemotherapy-treated patients with breast cancer
Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such…
Updated APHINITY trial data show addition of pertuzumab to trastuzumab plus chemotherapy continues to yield clinical benefit in patients with operable HER2-positive early breast cancer
Data from six-year analysis of the APHINITY trial showed that adding pertuzumab to the previous…
First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with…
Study finds key metabolic changes in patients with chemotherapy-associated cardiotoxicity
More and more patients are being treated successfully for cancer. However, some cancer treatments that…
Drug could alleviate side effects of chemo for breast cancer patients
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which…
Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug
An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block…